A randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of a single oral administration of recombinant human chymotrypsin lyophilized powder in healthy subjects
Latest Information Update: 06 Aug 2024
At a glance
- Drugs OsrhCT (Primary)
- Indications Pleurisy
- Focus Adverse reactions
- Sponsors Wuhan Healthgen Biotechnology
Most Recent Events
- 05 Aug 2024 New trial record